2021 Revenues ($USD) : $25,979,000,000
2021 R&D spend : $4,819,000,000
2021 Number of Employees : 24,200
Fiscal Year End : 12/31/2021
Leader : CEO Robert Bradway

Amgen’s revenues grew 2% in 2021, hitting a company record of $26 billion. The Thousand Oaks, California–based company scored two notable FDA approvals. Lumakras/Lumykras became the first medicine to win approval for KRAS G12C-mutated non-small cell lung cancer. In December 2021, Tezsire became the first FDA-approved biologic for severe asthma without a phenotype or biomarker limitation within its approved label. Also in 2021, the company won an expanded indication for Otezla (apremilast) to treat adults with plaque psoriasis, regardless of severity level. In November 2021, Amgen was named to the Dow Jones Sustainability World Index for the eighth consecutive year. The company aims to become carbon neutral by 2027 and reduce water use by 40% and waste disposal by 75% in the same time frame. —BB